Metraipolis › archive › dc_73939d30451d
Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42827135
- DOI
- 10.1038/s41408-[numero omesso]-1
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T05:17:15.842Z
- SHA-256 of the archived text
ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10- Stable URL of this page
https://metraipolis.com/documento/dc_73939d30451d
How to cite
Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135 — Europe PMC (en), https://europepmc.org/article/MED/42827135 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_73939d30451d (Metraipolis archive dc_73939d30451d, sha256 ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10)
BibTeX
@misc{dc73939d30451d,
title = {Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42827135},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_73939d30451d; sha256 ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42827135. Agents can read the archived copy with the MCP tool read_document.